IBI112

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

1

Daliresp

AstraZeneca

Phase 3

52

Zasocitinib

Takeda

Phase 3

13

D-2570

IInventisBio Co., Ltd

Phase 3

44

TAK-279

Takeda

Phase 3

35

Ponvory

VVanda Pharmaceuticals

Phase 3

16

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3

27

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

48

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

39

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

310

IDP-118 Lotion

BBausch Health Americas, Inc.

Phase 3

8Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Psoriasis4 trials

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06049810·566 enrolled

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT05645627·500 enrolled

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07265284·104 enrolled

Show 1 more trial

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT05003531·250 enrolled

Single Dose1 trial

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04511624·46 enrolled

Details

Drug Info

Related News